Nanexa AB (publ) (STO: NANEXA)

Market Cap	340.60M
Revenue (ttm)	50.76M
Net Income (ttm)	-64.42M
Shares Out	135.70M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	493,672
Open	2.420
Previous Close	2.420
Day's Range	2.420 - 2.600
52-Week Range	0.600 - 3.150
Beta	1.77
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 19, 2025

About Nanexa AB

Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia; NEX-20 for the treatment of multiple myeloma; and NEX-22 for the treatment of type 2 diabetes. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 19
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: NANEXA

Financial Performance

In 2023, Nanexa AB's revenue was 59.16 million, an increase of 117.72% compared to the previous year's 27.17 million. Losses were -76.40 million, 30.4% more than in 2022.